Trials & Filings

US Oncology, BioMarin Partner on Phase III BMN 673 Study

To investigate safety and effectiveness in breast cancer with BRCA1 or BRCA2 gene mutations

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

US Oncology Research is collaborating with BioMarin Pharmaceutical on a Phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients who test positive for BRCA1 or BRCA2 gene mutations. The study will investigate the effectiveness and safety of BMN 673. Thirteen U.S. Oncology Research affiliated practices with 56 locations will participate in the study.   The Phase III, open-label, randomized, parallel, 2-arm, multi-center study of BMN 673 versus phys...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters